Rubius Therapeutics, Inc. (NASDAQ:RUBY) rose Monday, on trial results from ongoing Phase 1/2 trial of RTX-240 in advanced solid tumors at the American Association of Cancer Research Meeting next month.
The company, out of Cambridge, Mass., which genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced initial clinical, pharmacodynamic and tumor trafficking data from its ongoing Phase 1/2 clinical trial of RTX-240 in patients with advanced solid tumors. The Company also shared tumor trafficking data from one patient with relapsed/refractory acute myeloid leukemia (AML) in the second Phase 1 arm of the study.
The Company believes these data provide initial proof-of-concept of the RED PLATFORM ® by providing evidence that red blood cells can be engineered to mimic the human immune system and stimulate adaptive and innate immunity to generate clinical responses in cancer patients with refractory disease.
Said Christina Coughlin, the company’s chief medical officer, “These initial data are incredibly exciting and demonstrate that RTX-240 has the potential to generate single-agent activity in patients with solid tumors, including a cold tumor such as metastatic uveal melanoma, where other treatments have failed to induce responses in patients,
“The encouraging safety results, including a single event of Grade 1 liver toxicity, and preliminary efficacy data for RTX-240 to date give us the potential to realize the power of immune agonists for the treatment of cancer.”
RUBY shares hiked $2.85, or 17.4%, to $19.28.